Overview

A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy

Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
Phase:
Phase 4
Details
Lead Sponsor:
David M. Simpson
Collaborator:
CSL Behring
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin